Utility of Biopsy in Kidney Transplants With Delayed Graft Function and Acute Dysfunction

2007 ◽  
Vol 39 (2) ◽  
pp. 376-377 ◽  
Author(s):  
D.M. Silva ◽  
J.P. Garcia ◽  
A.R. Ribeiro ◽  
F.J. Veronese ◽  
M.I. Edelweiss ◽  
...  
2019 ◽  
Vol 51 (5) ◽  
pp. 1568-1570 ◽  
Author(s):  
F.S. Gorayeb-Polacchini ◽  
H.C. Caldas ◽  
C.R. Gauch ◽  
M.A.S. Ferreira-Baptista ◽  
I.M.M. Fernandes-Charpiot ◽  
...  

1988 ◽  
Vol 45 (2) ◽  
pp. 346 ◽  
Author(s):  
John M. Barry ◽  
Norman Shively ◽  
Bette Hubert ◽  
Thomas Hefty ◽  
Douglas J. Norman ◽  
...  

2008 ◽  
Vol 22 (4) ◽  
pp. 418-423 ◽  
Author(s):  
Robert Öllinger ◽  
Pamela Kogler ◽  
Matthias Biebl ◽  
Michael Sieb ◽  
Robert Sucher ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Hilana H. Hatoum ◽  
Anita Patel ◽  
K. K. Venkat

Delayed graft function (DGF) of kidney transplants increases risk of rejection. We aimed to assess the utility of weekly biopsies during DGF in the setting of currently used immunosuppression and identify variables associated with rejection during DGF. We reviewed all kidney transplants at our institution between January 2008 and December 2011. All patients received rabbit antithymocyte globulin/Thymoglobulin (ATG) or Basiliximab/Simulect induction with maintenance tacrolimus + mycophenolate + corticosteroid therapy. Patients undergoing at least one weekly biopsy during DGF comprised the study group. Eighty-three/420 (19.8%) recipients during this period experienced DGF lasting ≥1 week and underwent weekly biopsies until DGF resolved. Biopsy revealed significant rejection only in 4/83 patients (4.8%) (one Banff 1-A and two Banff 2-A cellular rejections, and one acute humoral rejection). Six other/83 patients (7.2%) had Banff-borderline rejection of uncertain clinical significance. Four variables (ATG versus Basiliximab induction, patient age, panel reactive anti-HLA antibody level at transplantation, and living versus deceased donor transplants) were statistically significantly different between patients with and without rejection, though the clinical significance of these differences is questionable given the low incidence of rejection. Conclusions. Under current immunosuppression regimens, rejection during DGF is uncommon and the utility of serial biopsies during DGF is limited.


2017 ◽  
Vol 3 (5) ◽  
pp. e155 ◽  
Author(s):  
Helio Tedesco-Silva ◽  
Juliano Chrystian Mello Offerni ◽  
Vanessa Ayres Carneiro ◽  
Mayara Ivani de Paula ◽  
Elias David Neto ◽  
...  

2008 ◽  
Vol 73 (7) ◽  
pp. 877-884 ◽  
Author(s):  
E.C. Aquino-Dias ◽  
G. Joelsons ◽  
D.M. da Silva ◽  
R.H. Berdichewski ◽  
A.R. Ribeiro ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document